Boston Life Sciences Announces the Appointment of Henry Brem, M.D. and Gary Frashier to the Board of Directors
February 06 2007 - 1:43PM
PR Newswire (US)
HOPKINTON, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI), a biotechnology company focused on
diagnostic and therapeutic products for central nervous system
disorders, today announced the appointment of Dr. Henry Brem and
Gary Frashier as new members of the Company's Board of Directors.
"We welcome both of these highly qualified individuals to the
Boston Life Sciences board," comments Peter G. Savas, Chairman and
CEO. "I believe that the right board is made up of people who:
believe in the potential social and economic value of the Company's
programs; bring an inventory of complimentary skills, experiences
and relationships; and work effectively together with each other,
the officers and the shareholders. As a physician, neurosurgeon and
director of neurosurgery for Johns Hopkins, Henry provides medical
and clinical perspective to the board. His experience on advisory
boards of biotech, major pharmaceutical and professional
organizations will provide invaluable knowledge as we develop and
execute our product strategies in nerve repair. Gary brings over 25
years of experience as a CEO and independent director of a variety
of drug development and biotechnology companies. This experience
and operational knowledge will be of immense benefit to our
company." Henry Brem, M.D., has been a professor at Johns Hopkins
University School of Medicine since 1984. He serves as the Director
of the Department of Neurosurgery, Harvey Cushing Professor of
Neurosurgery, Professor of Ophthalmology, and Oncology. He is also
Director of the Hunterian Neurosurgical Research Laboratory. Dr.
Brem obtained his bachelor's degree from NYU and received his
medical degree from Harvard Medical School. He trained in surgery
at the Peter Bent Brigham Hospital in Boston and in neurosurgery at
the Neurological Institute of New York at Columbia University. Brem
has authored more than 150 articles in scientific journals. He is
responsible for developing Gliadel(R) wafer, a brain cancer
treatment, from concept through FDA approval. Dr. Brem holds
several patents for therapeutic agents and delivery methods. Gary
Frashier, through his company Management Associates, has been a
strategic consultant to emerging growth companies in the life
sciences field for the last five years. From 1990 until September
1998, he served as Chief Executive Officer of OSI Pharmaceuticals,
Inc., a biotechnology company, and, from January 1997 until
September 2000, as its Chairman of the Board. From 1987 until 1990,
he served as President and CEO of Genex Corporation, a protein
engineering company, and from 1984 until 1987, as Chairman and CEO
of Continental Water Systems, Inc., a manufacturer and marketer of
equipment to produce high purity water used by the pharmaceutical,
medical, electronics and research industries. Mr. Frashier also
served as Executive Vice President of Millipore Corporation, a
provider of products and services to biopharmaceutical,
manufacturing, clinical, analytical and research laboratories, and
President of Millipore's Waters Associates subsidiary. Mr. Frashier
serves on the Board of Directors of Tanox Inc., a Texas-based
biopharmaceutical company, and Inex Pharmaceuticals Corporation, a
Canadian- based biopharmaceutical company. Mr. Frashier has a B.S
in Chemical Engineering from Texas Tech University and received his
M.B.A. from the Massachusetts Institute of Technology. The other
current members of the Boston Life Sciences, Inc. board are William
Guinness, Robert Langer, Michael Mullen, John Preston and Peter
Savas. About Boston Life Sciences, Inc. Boston Life Sciences, Inc.
(BLSI) is engaged in the research and clinical development of
diagnostic and therapeutic products for central nervous system
(CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase
III clinical trials for the diagnosis of Parkinson's Disease (PD)
and Phase II clinical trials for the diagnosis of Attention Deficit
Hyperactivity Disorder (ADHD). Cethrin(R), a
recombinant-protein-based drug designed to promote nerve repair
after acute spinal cord injury, has reported positive interim
results in a Phase I/IIa clinical trial. The company's research and
pre-clinical CNS programs include Inosine for the treatment of
spinal cord injury and stroke, a DAT blocker for the treatment of
Parkinson's disease, and a second generation technetium-based
molecular imaging agent for PD and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital Boston. Gliadel(R) wafer is a trademark of MGI Pharma.
Safe Harbor The foregoing release contains certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward- looking statements include statements
regarding Boston Life Sciences' future expectations, beliefs,
intentions, goals, strategies, plans or prospects regarding the
future, including the development and commercialization of
ALTROPANE and Cethrin, the prospects of the Company's CNS
therapeutics program, the Company's strategies to develop and
commercialize axon regeneration technologies and the breadth of the
Company's technologies and intellectual property portfolio.
Forward- looking statements can be identified by terminology such
as "anticipate," "believe," "could," "could increase the
likelihood," "estimate," "expect," "intend," "is planned," "may,"
"should," "will," "will enable," "would be expected," "look
forward," "may provide," "would" or similar terms, variations of
such terms or the negative of those terms. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors including those risks, uncertainties and factors referred
to in the Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2006 filed with the Securities and Exchange
Commission under the section "Risk Factors," as well as other
documents that may be filed by Boston Life Sciences from time to
time with the Securities and Exchange Commission. As a result of
such risks, uncertainties and factors, the Company's actual results
may differ materially from any future results, performance or
achievements discussed in or implied by the forward-looking
statements contained herein. Boston Life Sciences is providing the
information in this press release as of this date and assumes no
obligations to update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life
Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT:
Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360 ext
224, or Web site: http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From May 2024 to Jun 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Jun 2023 to Jun 2024